miR-34a and miR-21 as biomarkers in evaluating the response of chemo-radiotherapy in Egyptian breast cancer patients

Shaban, Nadia Z.; Ibrahim, Nashwa K; Saada, Helen N.; El‐Rashidy, Fatma H.; Shaaban, Heba; Farrag, Mostafa A.; Debaiky, Khalid; Kodous, Ahmad S.

doi:10.1016/j.jrras.2022.08.001

Cited by 14 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even downregulated, the highest levels of miR-34a in our study were measured in non-luminal HER2 and luminal HER2 molecular subtypes. Shaban et al (2022) evaluated this miRNA as a response to treatment. miR-34a was downregulated in the pre-treatment phase and after chemo-radiotherapy miR-34a levels increased significantly, proving to be a promising biomarker in the evaluation of response to treatment.…”

Section: Resultsmentioning

confidence: 99%

MicroRNA as a promising molecular biomarker in the diagnosis of breast cancer

Miranda,

Slaibi-Filho,

Calasans dos Santos

et al. 2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

Introduction: Breast cancer represents the most prevalent malignancy among women. Recent advancements in translational research have focused on the identification of novel biomarkers capable of providing valuable insights into patient outcomes. Furthermore, comprehensive investigations aimed at discovering novel miRNAs, unraveling their biological functions, and deciphering their target genes have significantly contributed to our understanding of the roles miRNAs play in tumorigenesis. Consequently, these investigations have facilitated the way for the development of miRNA-based approaches for breast cancer prognosis, diagnosis, and treatment. However, conducting a more extensive array of studies, particularly among diverse ethnic groups, is imperative to expand the scope of research and validate the significance of miRNAs. This study aimed to assess the expression patterns of circulating miRNAs in plasma as a prospective biomarker for breast cancer patients within a population primarily consisting of individuals from Black, Indigenous, and People of Color (BIPOC) communities.Methods: We evaluated 49 patients with breast cancer compared to 44 healthy women.Results and discussion: All miRNAs analyzed in the plasma of patients with breast cancer were downregulated. ROC curve analysis of miR-21 (AUC = 0.798, 95% CI: 0.682–0.914, p <0.0001), miR-1 (AUC = 0.742, 95% CI: 0.576–0.909, p = 0.004), miR-16 (AUC = 0.721, 95% CI: 0.581–0.861, p = 0.002) and miR-195 (AUC = 0.672, 95% CI: 0.553–0.792, p = 0.004) showed better diagnostic accuracy in discrimination of breast cancer patients in comparison with healthy women. miR-210, miR-21 showed the highest specificities values (97.3%, 94.1%, respectively). Following, miR-10b and miR-195 showed the highest sensitivity values (89.3%, and 77.8%, respectively). The panel with a combination of four miRNAs (miR-195 + miR-210 + miR-21 + miR-16) had an AUC of 0.898 (0.765–0.970), a sensitivity of 71.4%, and a specificity of 100.0%. Collectively, our results highlight the miRNA combination in panels drastically improves the results and showed high accuracy for the diagnosis of breast cancer displaying good sensitivity and specificity.

show abstract

Section: Resultsmentioning

confidence: 99%

MicroRNA as a promising molecular biomarker in the diagnosis of breast cancer

Miranda,

Slaibi-Filho,

Calasans dos Santos

et al. 2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…Regarding PC3 cells, it would be intriguing to assess the expression levels of potential targets of miR-34a that exhibit notable expression, such as BCL2 and other relevant candidates. miR-34a has demonstrated the capability to impede proliferation, migration, motility, and invasion, while promoting apoptosis and senescence through its interactions with some key molecular targets, including SATB2, MYC, E2F3, NOTCH1, MET, AXL, and CDK4/6 [ 73 , 74 , 75 , 76 , 77 ].…”

Section: Discussionmentioning

confidence: 99%

Thymoquinone Potentially Modulates the Expression of Key Onco- and Tumor Suppressor miRNAs in Prostate and Colon Cancer Cell Lines: Insights from PC3 and HCT-15 Cells

Osorio-Pérez,

Estrada-Meza,

Ruiz-Manriquez

et al. 2023

Genes

View full text Add to dashboard Cite

Prostate cancer (PC) and colon cancer significantly contribute to global cancer-related morbidity and mortality. Thymoquinone (TQ), a naturally occurring phytochemical found in black cumin, has shown potential as an anticancer compound. This study aimed to investigate the effects of TQ on the expression profile of key tumor suppressor and onco-suppressor miRNAs in PC3 prostate cancer cells and HCT-15 colon cancer cells. Cell viability assays revealed that TQ inhibited the growth of both cell lines in a dose-dependent manner, with IC50 values of approximately 82.59 μM for HCT-15 and 55.83 μM for PC3 cells. Following TQ treatment at the IC50 concentrations, miRNA expression analysis demonstrated that TQ significantly downregulated miR-21-5p expression in HCT-15 cells and upregulated miR-34a-5p, miR-221-5p, miR-17-5p, and miR-21-5p expression in PC3 cells. However, no significant changes were observed in the expression levels of miR-34a-5p and miR-200a-5p in HCT-15 cells. The current findings suggest that TQ might exert its antiproliferative effects by modulating specific tumor suppressor and onco-suppressor miRNAs in prostate and colon cancer cells. Further investigations are warranted to elucidate the precise underlying mechanisms and to explore the therapeutic potential of TQ in cancer treatment. To the best of our knowledge, this is the first report regarding the effect of TQ on the miRNA expression profile in colon and prostate cancer cell lines.

show abstract

“…Some miRNA expression levels, such as miR-375 and miR-9, were strongly associated with ER+ BC. Other miRNAs' expression levels changed after treatment [39][40][41]. A different type of cancer was found to have higher miR-21 expression levels.…”

Section: Breast Cancer and Micro-rnasmentioning

confidence: 97%

MiRNAs as Promising Therapeutic Targets for Breast Cancer

Fakhry,

Abdel-Hamed,

Mesbah

et al. 2024

OBM Genet

View full text Add to dashboard Cite

Breast cancer (BC) is the most common cause of cancer-related death and is the malignancy most frequently diagnosed in females worldwide. BC incidence is predicted to continue increasing worldwide. Without interventions, annual new cases will reach over 3 million by 2030. Genetic abnormalities account for almost 70% of all BC cases worldwide. Biological pathways implicated include non-coding RNAs (ncRNAs). MiRNAs are small non-coding RNA molecules that play a role in post-transcriptional regulation of gene expression. They can function as either tumor suppressors or oncogenes, and their role depends on the specific miRNA and target genes affected. The research on miRNA-based cancer treatments has yielded promising results. Depending on recent data, the goal of this review was to summarize the mechanisms that explain the role of some miRNAs in BC pathogenesis and drug resistance. However, highlighting the areas needing further exploration and more research is required before using microRNAs in clinical settings.

show abstract

miR-34a and miR-21 as biomarkers in evaluating the response of chemo-radiotherapy in Egyptian breast cancer patients

Cited by 14 publications

References 31 publications

MicroRNA as a promising molecular biomarker in the diagnosis of breast cancer

MicroRNA as a promising molecular biomarker in the diagnosis of breast cancer

Thymoquinone Potentially Modulates the Expression of Key Onco- and Tumor Suppressor miRNAs in Prostate and Colon Cancer Cell Lines: Insights from PC3 and HCT-15 Cells

MiRNAs as Promising Therapeutic Targets for Breast Cancer

Contact Info

Product

Resources

About